Results of European post-marketing surveillance of bosentan in pulmonary hypertension

European Respiratory Journal

Volumn 30, Issue 2, 2007, Pages 338-344

  Humbert, Marc ^a   Segal, E S ^b   Kiely, D G ^c   Carlsen, J ^d   Schwierin, B ^b   Hoeper, M M ^e  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d Rigshospitalet   (Denmark)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Aminotransferase elevation; Bosentan; Post marketing surveillance; Pulmonary arterial hypertension

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; PROSTACYCLIN; PROSTANOID; SILDENAFIL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; FEMALE; FUNCTIONAL ASSESSMENT; HOSPITALIZATION; HUMAN; INCIDENCE; INTERNET; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIHYPERTENSIVE AGENTS; EUROPE; HUMANS; HYPERTENSION, PULMONARY; INTERNET; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; SULFONAMIDES;

EID: 34547558919     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00138706     Document Type: Article

References (9)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
3. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. S, 13S-24S.
4. Channnick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001; 358: 1119-1123.
5. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
6. Segal ES, Valette C, Oster L, et al. Risk management strategies in the postmarketing period: safety experience with the US and European bosentan surveillance programmes. Drug Saf 2005; 28: 971-980.
7. Björnsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther 2006; 79: 521-528.
8. European Medicines Agency. EPARs for authorised medicinal products for human use. Tracleer European public Assessment Report. www.emea.europa.eu/humandocs/Humans/EPAR/tracleer/tracleer.htm Date last accessed: May 2007.
9. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005; 25: 502-508.